Semazic^TM

Indication:
• An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
• To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease

Dosage & Administration:
The starting dose is 0.25 mg Semaglutide once weekly. After 4 weeks the dose should be increased to 0.5 mg once weekly. After at least 4 weeks with a dose of 0.5 mg once weekly, the dose can be increased to 1 mg once weekly to further improve glycemic control. Semaglutide is to be injected subcutaneously in the abdomen, thigh or in upper arm. Semaglutide should not be administered intravenously or intramuscularly.

Preparation:
Semazic^TM 0.25 mg Injection: Each box contains 1 pre-filled syringe of Semaglutide 0.25 mg Injection.
Semazic^TM 0.50 mg Injection: Each box contains 1 pre-filled syringe of Semaglutide 0.50 mg Injection.